Neurotrophic keratitis

May 14, 2020

RegeneRx Joint Venture Announces Efficacy Results of Neurotrophic Keratopathy Phase 3 Clinical Trial with RGN-259

Apr 24, 2020

2020 Market Analysis for the Global Neurotrophic Keratitis Market, Featuring Key Company Profiles Including Novartis, CooperVision and Bayer AG

Feb 03, 2020

RegeneRx Partner Updates on Phase 3 Dry Eye Trial

Dec 16, 2019

First Patient Enrolled in Mallinckrodt Phase 4 Trial of Acthar® Gel (Repository Corticotropin Injection) for Severe Keratitis

Jun 25, 2019

Dompé Announces First Patient Enrollment in Phase 2b Clinical Trial Investigating Novel Mechanism of Action in Moderate to Severe Dry Eye Disease

Jan 03, 2019

Dompé announces first treatment with Oxervate(TM) eye drops (cenegermin-bkbj), for neurotrophic keratitis (NK)

Aug 22, 2018

Dompé receives FDA approval of Oxervate(TM) eye drops (cenegermin-bkbj ophthalmic solution), first-in-class recombinant human nerve growth factor with potential to completely heal rare neurotrophic keratitis

Apr 25, 2018

GtreeBNT Discloses Preliminary Observations from Seventeen NK Patients Treated with RGN-259 Eye Drops

Jul 20, 2017

Cenegermin Eye Drops Receive European Union Approval: The First Biotechnological Drug Resulting from Dompé Research for the Treatment of Moderate to Severe Neurotrophic Keratitis is Made in Italy